Streetbeat News

SNPX

Synaptogenix, Inc.

https://www.synaptogen.com

Industry

Biotechnology

Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York.

Open

2.56

Mkt cap

3.3M

Volume

22K

High

2.56

P/E Ratio

0.23

52-wk high

8.78

Low

2.32

Div yield

N/A

52-wk low

2.32

Synaptogenix Inc (NASDAQ:SNPX) announced a 1-for-25 reverse stock split to meet Nasdaq's minimum bid price requirement. The reverse split will reduce outstanding shares to about 1,085,333, affecting all shareholders uniformly. This move is aimed at increasing the per-share trading price, with trading on a split-adjusted basis starting on Friday.

Portfolio Pulse from Henry Khederian

April 04, 2024 | 3:49 pm

Synaptogenix announced a 1-for-25 reverse stock split, leading to its shares trading lower.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 3:07 pm

Synaptogenix has announced a 1-for-25 reverse stock split, a strategic move aimed at maintaining its Nasdaq listing. This decision reflects the company's efforts to comply with Nasdaq's minimum share price requirement, a common practice among companies facing delisting risks.

Portfolio Pulse from Benzinga Newsdesk

April 03, 2024 | 12:17 pm

In Thursday's after-market session, health care stocks saw significant movements. Geron (GERN) led the gainers with a 90.8% increase, while Kineta (KA) experienced the largest drop among the losers, declining by 8.3%. Notably, Akebia Therapeutics (AKBA) rose by 8.02% following its Q4 earnings report.

Portfolio Pulse from Benzinga Insights

March 14, 2024 | 9:33 pm

Etsy shares fell by around 8% after reporting mixed Q4 financial results, missing earnings estimates but beating sales forecasts. Other stocks showed significant movements, with La Rosa Holdings, BuzzFeed, and Monopar Therapeutics among the top gainers, while Draganfly, Greenbrook TMS, and Synaptogenix led the losers. Notable movements were also seen in companies like Rivian Automotive, Lucid Group, and Sunnova Energy due to various announcements and financial results.

Portfolio Pulse from Avi Kapoor

February 22, 2024 | 6:38 pm

Health care stocks experienced significant movements in Thursday's intraday session. Monopar Therapeutics and Calidi Biotherapeutics led the gainers with over 75% increases in their stock prices, while Synaptogenix and Motus GI Holdings were among the top losers, with over 20% declines. Notably, Amylyx Pharma and SenesTech released their Q4 earnings, influencing their stock movements.

Portfolio Pulse from Benzinga Insights

February 22, 2024 | 5:31 pm

In Thursday's pre-market session, several healthcare stocks showed significant movement. Agile Therapeutics, Venus Concept, and Monopar Therapeutics were among the top gainers, with stock prices increasing by 82.4%, 72.95%, and 71.91% respectively. Ocular Therapeutix, Indivior, and Apyx Medical also saw notable gains. On the downside, Synaptogenix, Motus GI Holdings, and Chemomab Therapeutics led the losers, with their stock prices falling by 20.9%, 18.19%, and 9.69% respectively. Other stocks that experienced declines include Agape ATP, China Pharma Holding, and Cadrenal Therapeutics.

Portfolio Pulse from Benzinga Insights

February 22, 2024 | 1:06 pm

NVIDIA Corporation (NASDAQ:NVDA) shares surged 14.3% in pre-market trading after reporting Q4 financial results that exceeded expectations and provided strong Q1 revenue guidance. Other stocks also moved significantly in pre-market trading, with notable gainers including Agile Therapeutics, BuzzFeed, and Elevai Labs, among others. On the losing side, Draganfly, Synaptogenix, and Bel Fuse experienced significant drops following various announcements.

Portfolio Pulse from Avi Kapoor

February 22, 2024 | 12:55 pm

In Wednesday's after-market session, several healthcare stocks experienced significant movements. Virpax Pharmaceuticals, Talphera, Brainstorm Cell, NKGen Biotech, 180 Life Sciences, and ENDRA Life Sciences were among the gainers, with increases ranging from 7.14% to 12.3%. Conversely, Synaptogenix, Portage Biotech, Bright Green, Motus GI Holdings, Fresh2 Group, and Biofrontera were the losers, with their stock prices declining between 6.86% and 19.6%.

Portfolio Pulse from Benzinga Insights

February 21, 2024 | 9:31 pm

Synaptogenix has received a notice of allowance for its U.S. patent application 17/665,033, which covers halogenated esters of cyclopropanated unsaturated fatty acids for use in treating neurodegenerative diseases. This development marks a significant milestone for the company in its efforts to develop treatments for conditions such as Alzheimer's disease.

Portfolio Pulse from Benzinga Newsdesk

February 21, 2024 | 8:58 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.